Taking all together, the above findings provide a new theoretical basis for expanding this epigenetic investigations to a more large cohort of EGFR-mutated NSCLCs and suggest a possible role of GABBR2 in improving clinical outcomes of TKI treated patients with locally advanced NSCLC (47). This evidence concerns the gene EGFR and non-small cell lung carcinoma.